Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma

Recent studies have demonstrated that HER2 and MET receptor tyrosine kinases are co-overexpressed in a subset esophageal adenocarcinoma (EAC). We therefore studied the usefulness of combining HER2 and MET targeting by small-molecule inhibitors lapatinib and foretinib, respectively, both in in-vitro...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassan, Md. Sazzad, Williams, Fiona, Awasthi, Niranjan, Schwarz, Margaret A., Schwarz, Roderich E., Li, Jun, von Holzen, Urs
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879590/
https://www.ncbi.nlm.nih.gov/pubmed/31772236
http://dx.doi.org/10.1038/s41598-019-54129-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879590/
https://www.ncbi.nlm.nih.gov/pubmed/31772236
http://dx.doi.org/10.1038/s41598-019-54129-7

Ejemplares similares